Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
12
|
pubmed:dateCreated |
1998-2-5
|
pubmed:abstractText |
Flow cytometric expression of bcl-2 protein was analyzed in 90 newly diagnosed acute myeloblastic leukemia (AML) patients using an anti-bcl-2 monoclonal antibody by direct immunofluorescence technique and results were correlated with FAB cytotype, CD34 expression and clinical outcome. Bcl-2 was expressed in all AML cases with different intensity. The mean fluorescence index (MFI), expressed as the ratio of sample mean channel:control mean channel, ranged from 3.0 to 39.5 with a median value of 14. The MFI was significantly higher (P = 0.01) in M0 (20.9) and M1 (18.3) than in M2 (11.7), M3 (12.4), M4 (11.8) and M5 (9.5) cytotypes. In addition, bcl-2 MFI significantly correlated both with CD34 positivity (P = 0.001) and with CD34 MFI (P = 0.01), being CD34 antigen expressed in 65% of patients with a bcl-2 MFI >14, and only in 35% of AML cases with a bcl-2 MFI >14. When bcl-2 intensity expression was correlated with complete remission (CR) rate, a higher MFI was associated with a low CR rate after standard intensive chemotherapy. In particular, CR was achieved in 86% of patients with a bcl-2 MFI <14, but only in 57% of patients with a MFI >14 (P = 0.008). A further decrease of CR rate to 41% was observed in patients in whom a higher bcl-2 MFI was coupled with the presence of CD34 antigen on their blasts. By statistical analysis we also demonstrated that both bcl-2 high MFI (>14) and CD34 expression are independent prognostic factors for achieving CR in AML. These data raise the hypothesis that high values of bcl-2 may confer on myeloid blasts a higher resistance to standard chemotherapy. However, identification of patients with high expression of bcl-2 may be important for a different therapeutic approach.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical | |
pubmed:status |
MEDLINE
|
pubmed:month |
Dec
|
pubmed:issn |
0887-6924
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:volume |
11
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
2075-8
|
pubmed:dateRevised |
2007-11-15
|
pubmed:meshHeading |
pubmed-meshheading:9447823-Adolescent,
pubmed-meshheading:9447823-Adult,
pubmed-meshheading:9447823-Aged,
pubmed-meshheading:9447823-Aged, 80 and over,
pubmed-meshheading:9447823-Antigens, CD34,
pubmed-meshheading:9447823-Female,
pubmed-meshheading:9447823-Humans,
pubmed-meshheading:9447823-Leukemia, Myeloid, Acute,
pubmed-meshheading:9447823-Male,
pubmed-meshheading:9447823-Middle Aged,
pubmed-meshheading:9447823-Prognosis,
pubmed-meshheading:9447823-Proto-Oncogene Proteins c-bcl-2
|
pubmed:year |
1997
|
pubmed:articleTitle |
High bcl-2 expression in acute myeloid leukemia cells correlates with CD34 positivity and complete remission rate.
|
pubmed:affiliation |
Cattedra di Ematologia, Università di Siena, Italy.
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|